ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1843

Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations

Allen P. Anandarajah1, Sean McMahon2, Amanda Ostronic3, Changyong Feng4, Jennifer Anolik5 and Christopher T. Ritchlin6, 1Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, 2Quality office, University of Rochester Medical Center, Rochester, NY, 3University of Rochester Medical Center, Rochester, NY, 4Statistics, University of Rochester, Rochester, NY, 5Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: access to care and high risk, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: We previously demonstrated that a small group of high risk, high cost patients (HRHC) account for majority of the hospitalizations, length of stay (LOS) and overall cost among all lupus patients admitted to an academic medical center. Herein, we assessed the impact of an intervention to improve access to rheumatology care for HRHC lupus patients by comparing the number of hospital admissions and LOS in the HRHC cohort compared to hospitalized lupus patients not meeting HRHC criteria.

Methods: Lupus patients who required 3 or more admissions over a 3-year period between 2013 and 2016 were categorized as HRHC patients. Most of these patients were from the poor, urban communities and were mostly African American. A project to improve quality for low-income, underprivileged, poor, underage, SLE (IQ-LUPUS) patients was started in July 2018. One of the goals of the IQ-LUPUS project is to enhance access for the HRHC patients to rheumatology care by offering direct access to a nurse care coordinator and a social worker who provide medical advice, remind and facilitate outpatient visits, enable educational activities and organize home visits. Additionally, we opened a clinic in the urban community. We compared the no show rates for the HRHC patients with all lupus patients and all rheumatology patients seen in the outpatient clinics at URMC for the fiscal year (FY) 2017 (prior to project) with FY 2018 (since starting project). We also determined the hospitalization rates and LOS for all admissions among the HRHC patients enrolled in the project, for first 10 months of FY 2017 with the first 10 months of FY 18. The gender, age and the diagnoses on admission were all documented.

Results: A total of 54 HRHC patients are enrolled in the IQ-LUPUS project to date. No show rates for these HRHC patients was 12.1% for FY 2017, 5.8% for all lupus patients and 4.3% for all patients seen at the Rheumatology clinic. The no show rates for the HRHC patients decreased 1.3% for FY 2018 (p=0.62) but increased in all lupus patients (0.8%) and all rheumatology patients (0.7%). In 2017, 16 of the HRHC patients had 52 admissions in 2017 for a total LOS of 231 days. All patients were female with a mean age of 32.9 years. In 2018, the number of admissions decreased to 36 (p=0.3). These admissions included 17 patients and a total LOS of 159 days (p=0.5)). All patients were female with a mean age of 32.5 years. The number of 30-day readmissions also decreased from 21 in 2017 to 14 in 2018. Although no statistical significance was noted early results of the IQ-LUPUS project suggests that improving access can decrease hospitalizations.

Conclusion:

Methods aimed at improving access to rheumatology care through care coordination and special clinics can decrease the number of hospitalizations and LOS among high risk SLE patients. Further studies are needed to further define and implement targeted interventions that decrease hospital admissions and improve quality of care for this vulnerable population.

High-Risk, High-Cost Lupus patients

All lupus patients

2017

2018

2017

218

No show rates

54 (12.1%)

43 (10.8%)

178 (5.8%)

147 (6.6%)

Admissions

52 (36.6%)

36 (21.3%)

142

169

Length of stay

231 (21.8%)

159 (12.9%)

1060

1225


Disclosure: A. P. Anandarajah, None; S. McMahon, None; A. Ostronic, None; C. Feng, None; J. Anolik, None; C. T. Ritchlin, AbbVie, Amgen, UCB, 2,AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer Inc, 5.

To cite this abstract in AMA style:

Anandarajah AP, McMahon S, Ostronic A, Feng C, Anolik J, Ritchlin CT. Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/improving-access-to-rheumatology-care-for-high-risk-lupus-patients-can-help-decrease-hospitalizations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-access-to-rheumatology-care-for-high-risk-lupus-patients-can-help-decrease-hospitalizations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology